Temasek Holdings Private Ltd Has $537.20 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Temasek Holdings Private Ltd decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.1% in the 3rd quarter, HoldingsChannel reports. The fund owned 1,107,590 shares of the medical research company’s stock after selling 35,897 shares during the period. Thermo Fisher Scientific makes up about 1.9% of Temasek Holdings Private Ltd’s investment portfolio, making the stock its 14th biggest holding. Temasek Holdings Private Ltd’s holdings in Thermo Fisher Scientific were worth $537,203,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of TMO. Main Street Research LLC increased its position in shares of Thermo Fisher Scientific by 8.5% during the third quarter. Main Street Research LLC now owns 996 shares of the medical research company’s stock valued at $483,000 after purchasing an additional 78 shares during the period. Nicolet Advisory Services LLC lifted its position in Thermo Fisher Scientific by 6.9% in the third quarter. Nicolet Advisory Services LLC now owns 2,569 shares of the medical research company’s stock worth $1,246,000 after purchasing an additional 166 shares during the period. Benchmark Investment Advisors LLC acquired a new stake in Thermo Fisher Scientific during the third quarter worth $230,000. Broyhill Asset Management LLC increased its holdings in Thermo Fisher Scientific by 530.0% in the 3rd quarter. Broyhill Asset Management LLC now owns 7,024 shares of the medical research company’s stock valued at $3,407,000 after buying an additional 5,909 shares during the period. Finally, Cadence Bank raised its stake in shares of Thermo Fisher Scientific by 3.2% in the 3rd quarter. Cadence Bank now owns 4,280 shares of the medical research company’s stock valued at $2,076,000 after buying an additional 131 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president directly owned 20,752 shares in the company, valued at approximately $11,230,982.40. This represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $463.99 on Friday. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67. The firm has a market cap of $172.36 billion, a PE ratio of 26.15, a price-to-earnings-growth ratio of 2.75 and a beta of 0.96. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company’s 50-day moving average price is $557.83 and its two-hundred day moving average price is $548.17.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company’s revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the business posted $6.10 earnings per share. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio is presently 9.70%.

Wall Street Analyst Weigh In

TMO has been the topic of several recent research reports. Evercore reiterated an “outperform” rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Citigroup raised their price target on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Friday, January 9th. Wells Fargo & Company set a $683.00 price objective on Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, UBS Group restated a “neutral” rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $633.68.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.